<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Heidi D Klepin, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bob Lowenberg, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H15842800">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognosis for older patients with acute myeloid leukemia (AML) is generally inferior to that in younger patients. However, there is no consensus definition of "older adult" regarding management of AML. Curative therapy for AML generally requires intensive chemotherapy and is associated with potentially severe complications. While clinical trials have used various age thresholds for eligibility, chronologic age is only one factor to be considered when selecting therapy for older adults with AML.
        </p>
        <p>
         Management of AML in older patients is challenging because they are more likely to have impaired functional status and/or comorbidities that can limit treatment options. Compared with younger patients, AML in older patients is also more likely to carry adverse cytogenetic features and be refractory to treatment.
        </p>
        <p>
         This topic review will discuss the pretreatment evaluation and prognosis of older adults with AML.
        </p>
        <p>
         Related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">
          "Systemic chemotherapy for cancer in older adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6273162">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H6273184">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall survival (OS) rates for AML decrease with increasing age  (
         <a class="graphic graphic_figure graphicRef75742" href="/z/d/graphic/75742.html" rel="external">
          figure 1
         </a>
         ). Outcomes might be better if more patients were offered treatment, and the availability of targeted agents and less toxic treatments is expected to increase the percentage of older adults who are treated for AML. (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults"
         </a>
         .)
        </p>
        <p>
         Most series of older patients with newly diagnosed AML have noted complete remission (CR) rates between 40 and 60 percent, with higher rates seen in more recent trials [
         <a href="#rid1">
          1-14
         </a>
         ]. While suitably selected older patients given intensive induction therapy may achieve CR at a rate approximating that of younger patients [
         <a href="#rid5">
          5
         </a>
         ], others may spend a significant proportion of their remaining life in a hospital setting receiving treatment [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         Registry data indicate that the median age for patients with AML is approximately 68 years, which is more than a decade older than the median age of patients commonly reported on clinical trials. Unfortunately, many older adults receive no therapy for this disease. An analysis of Surveillance, Epidemiology and End Results (SEER) data (2000 to 2007) linked to Medicare showed that less than half of newly diagnosed patients ≥65 years of age received any leukemia-directed therapy [
         <a href="#rid17">
          17
         </a>
         ]. An updated analysis (2000 to 2009) showed similar results with older age, comorbidity, and poor performance indicators associated with non-treatment [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Older age, variously defined in most studies as over age 55, 60, or 65 years, is a poor prognostic factor in AML. In comparison with younger patients, AML in older patients is generally more challenging to treat, as evidenced by the following characteristics [
         <a href="#rid1">
          1,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower percentage of favorable cytogenetics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher percentage of unfavorable cytogenetics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher incidence of multidrug resistance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher incidence of treatment-resistant disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower CR rates, shorter remission durations, and shorter median OS
        </p>
        <p>
        </p>
        <p>
         Older adults are also more likely to have comorbidities and a poorer performance status that increase treatment-related morbidity and mortality and limit intensive treatments such as allogeneic hematopoietic cell transplantation (HCT). Although age is one of the most important predictors of treatment-related mortality (TRM, eg, 30-day mortality), it is likely not an independent variable and largely acts as an indirect measure of other prognostic factors. This was best shown in an analysis of 3365 adults with newly diagnosed AML that created a scoring system to estimate TRM based on age, sex, race/ethnicity, performance status, laboratory features, and the presence or absence of secondary AML [
         <a href="#rid20">
          20
         </a>
         ]. The ability of the scoring system to predict TRM was similar whether or not age was incorporated; as such, older age by itself is not a contraindication to treatment.
        </p>
        <p>
         Outcomes might be better if more patients were offered chemotherapy. An analysis of Medicare claims for 2657 older patients with AML diagnosed between 1991 and 1996 underscored the grim prognosis for AML in the older patient [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Median survival for all patients was two months, with a two-year OS of 6 percent. For patients ≥85 years of age, median survival was only one month.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Only 30 percent of patients received chemotherapy; when compared with those not receiving chemotherapy, they tended to be younger (average age 73 versus 78 years) and live longer (median survival seven versus one month).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Of those older patients dying from AML during the follow-up period of the study (94 percent of the sample), 31 percent of their remaining days had been spent in an inpatient facility.
        </p>
        <p>
        </p>
        <p>
         Modest improvements were seen in an updated analysis using SEER/Medicare data for 5480 patients with newly diagnosed AML from 2000 to 2007 [
         <a href="#rid17">
          17
         </a>
         ]. In this cohort approximately 40 percent of patients received anti-leukemia therapy, with a median survival of two months in untreated patients versus six months in those who received any therapy. The largest improvements were seen in those aged 65 to 69 years (median survival 10 months, if treated). Analysis of 8336 patients using SEER/Medicare data with newly diagnosed AML from 2000 to 2009 again showed approximately 40 percent received any therapy; the rate increased to 50 percent by 2009 [
         <a href="#rid18">
          18
         </a>
         ]. Unadjusted survival was 2.5 months overall; compared with untreated patients, survival was longer for patients who were treated (5 months versus 1.5 months, respectively). In multivariate analysis, treated patients had a 33 percent lower risk of death compared with untreated. Analysis of 3637 patients ≥60 years in the PETHEMA registry reported 4.7 month OS, 29 percent one-year OS, and 7 percent five-year OS [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         A retrospective analysis of 2767 patients with AML (excluding those with acute promyelocytic leukemia) from the Swedish acute leukemia registry reported that rates of early death (ie, death within 30 days of diagnosis) were lower in patients receiving intensive induction chemotherapy when compared with those who received palliative therapy, even when stratified for performance status; however, it is possible that patients with a better prognosis were more likely to be offered induction chemotherapy [
         <a href="#rid2">
          2,23
         </a>
         ]. The difference between 30-day mortality rates for the two groups ranged from 16 to 35 percent. Patients who had de novo AML, were "fit" for intensive chemotherapy, had an Eastern Cooperative Oncology Group (ECOG) performance status of zero to 2, and were age 16 to 55, 56 to 65, 66 to 75, and 76 to 89 years had median OS times of 7 years, 18 months, 14 months, and 6 months, respectively.
        </p>
        <p>
         In addition, a study of 103 newly diagnosed patients with AML who received intensive chemotherapy suggested that the impact of treatment on quality of life and physical function (both self-reported and objectively measured) was similar between younger (range 21 to 59 years) and older (60 to 80 years) patients [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6273191">
         <span class="h2">
          Prognosis
         </span>
        </p>
        <p class="headingAnchor" id="H3543768763">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of risk factors have been identified that occur more frequently in the older patient with AML and appear to contribute to the worse outcomes  (
         <a class="graphic graphic_table graphicRef60295" href="/z/d/graphic/60295.html" rel="external">
          table 1
         </a>
         ). The major independent prognostic factors in older adults with AML are [
         <a href="#rid3">
          3,5,25-29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytogenetic and genetic abnormalities
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor performance status
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary leukemia (ie, after an antecedent hematologic disorder, such as myelodysplastic or myeloproliferative neoplasm)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy-related leukemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White blood cell count at diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multidrug resistance-1 (P-glycoprotein) expression
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CD34 expression
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mutation spectrum (eg,
         <em>
          TP53
         </em>
         ,
         <em>
          SRSF2
         </em>
         ,
         <em>
          SF3B1, U2AF1
         </em>
         ,
         <em>
          ZRSR2
         </em>
         ,
         <em>
          ASXL1
         </em>
         ,
         <em>
          EZH2
         </em>
         ,
         <em>
          BCOR
         </em>
         ,
         <em>
         </em>
         or
         <em>
          STAG2
         </em>
         ) [
         <a href="#rid30">
          30
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The effects of age, performance status, and comorbid conditions are discussed below, while prognostic factors common to all age groups (eg, cytogenetics, secondary leukemia) are presented in more detail separately. (See
         <a class="local">
          'Physical functioning'
         </a>
         below and
         <a class="local">
          'Comorbid conditions'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p>
         The cytogenetic abnormalities most often associated with treatment failure in young patients with AML (eg, abnormalities of chromosomes 5 or 7 or complex karyotypes) are considerably more common in older patients, occurring in 32 to 57 percent of patients in two series [
         <a href="#rid27">
          27,31-34
         </a>
         ]. Conversely, all of the "favorable" cytogenetic abnormalities, such as t(8;21), t(15;17), or inv(16), are more common in younger subjects and are responsible in part for their better disease-free survival  (
         <a class="graphic graphic_figure graphicRef65190" href="/z/d/graphic/65190.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid33">
          33-39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p>
         Data are available on the impact of recurring gene mutations in younger and older adults with AML. Mutations of
         <em>
          NPM1
         </em>
         and both alleles of
         <em>
          CEBPA
         </em>
         are favorable for outcome [
         <a href="#rid40">
          40,41
         </a>
         ], whereas internal tandem duplications of
         <em>
          FLT3
         </em>
         (FLT3-ITD) and mutations of
         <em>
          ASXL1
         </em>
         and
         <em>
          DNMT3A
         </em>
         are associated with poor outcomes in patients over age 60 years [
         <a href="#rid42">
          42-46
         </a>
         ]. In one study, older adults without mutations in genes recurrently mutated in myelodysplastic syndrome (
         <em>
          SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR,
         </em>
         or
         <em>
          STAG2
         </em>
         ) had response rates similar to those of younger de novo AML when treated with standard AML therapy [
         <a href="#rid30">
          30
         </a>
         ]. The role of genomic biomarkers in AML is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4094180842">
         <span class="h3">
          Prognostic models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prognostic models for older adults with AML incorporate chronologic age, cytogenetic information, and clinical variables. These models can provide useful information for risk stratification, although all rely on chronologic age as a surrogate for certain measurable patient-specific characteristics (ie, comorbidity, functional limitations) that may differ among individuals of similarly age. These models were primarily developed for consideration of intensive therapy.
        </p>
        <p>
         Data from a retrospective cohort of 1100 patients with AML aged 20 to 89 were used to develop an AML model to estimate the risk of mortality among patients who received treatment [
         <a href="#rid47">
          47
         </a>
         ]. The model included comorbidity burden (measured by the augmented HCT-CI, see below), age and cytogenetic/molecular risks and was updated using the 2017 European LeukemiaNet Risk Classification [
         <a href="#rid48">
          48
         </a>
         ]. Analysis of 2483 patients used data from two treatment trials of adults ≥60 years identified cytogenetic category, white blood cell (WBC) count, performance status, age, and secondary AML as significant factors for defining risk groups associated with OS [
         <a href="#rid26">
          26
         </a>
         ]. Other models also found association of age, WBC count, cytogenetics, and mutation status with survival [
         <a href="#rid49">
          49-51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15843336">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H15843344">
         <span class="h2">
          General
         </span>
         <span class="headingEndMark">
          —
         </span>
         The assessment of an older adult with AML includes evaluation of functional status and comorbid conditions.
        </p>
        <p>
         Detailed pretreatment evaluation of all patients with AML is presented separately, as is an overview of the comprehensive geriatric assessment of cancer patients. (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Pretreatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer"
         </a>
         .)
        </p>
        <p>
         Specific testing for older adults is presented in the following sections.
        </p>
        <p class="headingAnchor" id="H15843351">
         <span class="h2">
          Physical functioning
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient's performance status, self-reported ability to perform basic and instrumental activities of daily living, and physical performance are assessments of physical function that can help predict the ability to withstand rigorous chemotherapy regimens.
        </p>
        <p class="headingAnchor" id="H15843358">
         <span class="h3">
          Performance status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have demonstrated that measures of performance status provide prognostic information in older adults with AML, particularly for those with poor performance status at diagnosis. Both the Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status have been used as measures of physical functioning to inform prognosis in patients with AML  (
         <a class="graphic graphic_table graphicRef72901 graphicRef58785" href="/z/d/graphic/72901.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'Performance status'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of data from five Southwestern Oncology Group (SWOG) trials that included 968 patients with AML found that the mortality rate within 30 days of initiation of induction therapy is dependent on both the patient's age and ECOG performance status (PS) at diagnosis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thirty-day mortality rates were 2 to 3 percent for patients under the age of 55 years regardless of the PS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients over age 55 years, mortality rates ranged from 5 to 18 percent for patients with a PS of 0 or 1. Patients 55 to 65 years old with a PS of 2 had a similar mortality rate (18 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients over age 55 years with a PS of 3 and those over age 65 with a PS of 2 or 3 had much higher mortality rates that ranged from 29 to 82 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The proportion of patients with poorer performance status increased with age. PS of 2 or 3 was observed in 15, 24, 26, and 32 percent in those under age 56, 56 to 65, 66 to 75, and &gt;75 years of age, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The prognostic importance of poor performance status increased with age. Patients with ECOG PS 3 at the time of diagnosis had 30-day mortality rates of 29, 47, and 82 percent for age groups 56 to 65, 65 to 75, and &gt;75 years, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective analysis of 998 patients age 65 or greater (range 65 to 89; median 71 years) who underwent intensive induction chemotherapy reported eight-week mortality rates of 23, 40, and 72 percent for patients with ECOG PS of 0 to 1, 2, and 3 to 4, respectively [
         <a href="#rid15">
          15
         </a>
         ]. One-year overall survival (OS) rates for the same groups were 35, 25, and 7 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective study of 2767 patients with AML (excluding those with acute promyelocytic leukemia) from the Swedish acute leukemia registry also reported that older patients with an ECOG PS of 0 to 1 had 30-day death rates after intensive chemotherapy of less than 15 percent, while patients with a PS of 3 or 4 had higher early death rates regardless of patient age ranging from 26 to 36 percent [
         <a href="#rid2">
          2
         </a>
         ]. Seventy percent of patients up to age 80 years had a PS of 0 to 2. Of note, there were some long-term survivors in all age and PS groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective trial of induction chemotherapy with
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">
          daunorubicin
         </a>
         in 813 older adults (median age 67 years, range 60 to 83 years) with ECOG PS of 0 to 2 reported a 30-day mortality rate of 11 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Older adults may have impairments that are not adequately reflected in the performance status. This was best demonstrated in a single-institution feasibility study of an inpatient geriatric assessment in 54 patients with newly diagnosed AML &gt;60 years (median age 70.8 years) [
         <a href="#rid52">
          52
         </a>
         ]. Among the 38 patients with an ECOG PS ≤1, additional testing revealed the following impairments in at least one-quarter of patients: depression, distress, impairment in instrumental activities of daily living, impairment in activities of daily living, objectively measured physical impairment, cognitive impairment, and comorbidity; importantly, nearly two-thirds of patients were impaired in more than one domain. Studies investigating the prognostic significance of individual geriatric assessment domains are described below. The prognostic value of comprehensive geriatric assessment among older adults with AML is under investigation.
        </p>
        <p class="headingAnchor" id="H15843365">
         <span class="h3">
          Activities of daily living
         </span>
         <span class="headingEndMark">
          —
         </span>
         Geriatricians commonly measure functional status by evaluating basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). ADLs are the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADLs are required to live independently in the community and include activities such as shopping, managing finances, housekeeping, preparing meals, and taking medications. Assessment of ADLs and IADLs add to the functional status obtained from the ECOG or Karnofsky performance status [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among older adults with ECOG PS &lt;2 treated intensively for AML in a single institution study, limitations in ADLs and IADLs were prevalent (34.2 and 23.7 percent, respectively) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective trial of 63 adults (age 19 to 85) with newly diagnosed AML measured Karnofsky performance status (KPS) and IADL at diagnosis [
         <a href="#rid53">
          53
         </a>
         ]. Impaired KPS (&lt;80 percent) and impaired IADLs were noted in 33 and 25 percent of patients, respectively. Impairment in IADLs was associated with decreased rates of OS independent of age and KPS. However, fewer patients with IADL limitations received intensive chemotherapy compared with those without IADL limitations (46 versus 93 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A multi-center study investigating pretreatment geriatric assessment among older adults with newly diagnosed myelodysplastic syndrome (MDS) or AML found that ADL impairment was associated with worse OS among non-intensively treated patients independent of age, cytogenetics, or KPS [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective single institution study of 101 adults ≥65 years of age with newly diagnosed AML utilized questionnaire data from a quality of life survey (EORTC-QLQ C30) to determine whether specific screening questions that focused on physical, social, cognitive, psychologic, nutritional status, or pain were predictive of survival [
         <a href="#rid55">
          55
         </a>
         ]. Patients who reported difficulty with strenuous activities (eg, lifting a heavy shopping bag) had a twofold increased risk of death compared with those reporting less difficulty independent of tumor biology, ECOG score, comorbidity, or treatment allocation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6770091">
         <span class="h3">
          Physical performance tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nia.nih.gov%2Fresearch%2Flabs%2Fleps%2Fshort-physical-performance-battery-sppb&amp;token=Ngvz3u3Ql93gI9weXBPg6VtOf8n2HWudIoo%2FrOWiIs374avkeEunE01ednwN5QQaicfILokZzILD9X%2BBLpEalBGjmFaV%2FDZCQ%2BRn9ks0NDU%3D&amp;TOPIC_ID=86177" target="_blank">
          Short Physical Performance Battery
         </a>
         (SPPB) is a validated objective measure of lower extremity function that has been shown to predict future disability, hospitalizations, and mortality among older adult patients without AML [
         <a href="#rid56">
          56-64
         </a>
         ]. It includes measures of standing balance (timing of tandem, semi-tandem, and side-by-side stands), four-meter walking speed and ability, and time to rise from a chair five times. Total scores range from 0 to 12 and total scores &lt;9 are indicative of physical frailty and worse clinical outcome among older adults without cancer.
        </p>
        <p>
         While validation studies in AML are underway, it is reasonable to utilize the SPPB to objectively assess functional status when making treatment decisions in older adults with AML, particularly among those with ECOG PS &lt;3. This test can be performed in approximately five minutes by trained staff in the inpatient or outpatient setting using publically available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgeriatrictoolkit.missouri.edu%2FSPPB-Score-Tool.pdf&amp;token=5wT3OW6t96ZixB0HvIyK8nFpqXWUID%2Fh8hm1ob2%2FYqprL4Uhew86lCjIMI3yssOWd9OK5ykn4Bn4Dz%2B5uLiLjq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=86177" target="_blank">
          training modules
         </a>
         to facilitate standardization of testing.
        </p>
        <p>
         The following studies have evaluated physical performance tests in this setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective single center study evaluated the prognostic value of the SPPB in 74 older adults (≥60 years) with newly diagnosed AML undergoing induction chemotherapy [
         <a href="#rid65">
          65
         </a>
         ]. The mean age was 70 years and 78 percent had an ECOG PS ≤1. The median OS was 11 months, and the 30-day mortality rate was 15 percent. The median SPPB score was 8.5. When compared with those with higher scores, patients with an SPPB score &lt;9 had a shorter median survival (6.0 versus 16.8 months; hazard ratio [HR] 2.2, 95% CI 1.1-4.6). When analyzed as a continuous variable, each two-point increase in the SPPB score was associated with a 15 percent decrease in the HR for death (HR 0.85; 95% CI 0.72-1.01) controlling for age, sex, ECOG PS, cytogenetic risk, prior myelodysplastic syndrome, and hemoglobin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single center study evaluated patients ≥60 years old with the Wheatley index, a composite prognostic tool that includes pretreatment quality of life (QOL) and physical performance measures (PPMs; ie, hand grip strength, a two-minute walk test, and timed chair stands) [
         <a href="#rid66">
          66
         </a>
         ]. QOL and PPMs at diagnosis were not good predictors of one-year mortality, but patients with a poor Wheatley risk score had higher one-year mortality than patients who had good or standard scores.
        </p>
        <p>
        </p>
        <p>
         Differences between the two studies' results may relate to differences in the patient populations and/or the distinct measures of physical performance tests, which may not be equivalent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of the four-meter walk test (a subcomponent of SPPB) is a reasonable substitute for evaluating objective physical function. Usual gait speed is a consistent predictor of outcomes among older patients in varied settings [
         <a href="#rid67">
          67,68
         </a>
         ]. A registry analysis evaluated the predictive utility of four-meter usual gait speed among 448 adults aged 75 years or older seen at a single institution with a new diagnosis of hematologic malignancy [
         <a href="#rid69">
          69
         </a>
         ]. In this study, every decrease of 0.1 meters per second (m/s) in gait speed was associated with higher mortality (HR 1.2, 95% CI 1.12-1.29), odds of unplanned hospitalization (OR 1.33, 95% CI 1.16-1.51), and emergency department visits (OR 1.34, 95% CI 1.17-1.53). Those with the best survival had a gait speed faster than 0.8 m/s, while those with gait speed slower than 0.6 m/s had worse survival, regardless of ECOG performance status. These thresholds can be useful in clinical practice to identify patients with physical frailty.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15843372">
         <span class="h2">
          Comorbid conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Comorbid conditions are common among older adults with AML; analysis of over 5000 adults in the United States with newly diagnosed AML (median age 78 years, range 65 to 93) showed that approximately half had a claims-based diagnosis of at least one major comorbid condition [
         <a href="#rid17">
          17
         </a>
         ]. The presence of major comorbidity influences the treatment plan and is frequently associated with increased treatment risk and worse outcomes [
         <a href="#rid2">
          2,5,15,20,70,71
         </a>
         ].
        </p>
        <p>
         Many studies have shown a relationship between increased comorbidity burden and decreased remission rates, increased early mortality, and decreased OS [
         <a href="#rid17">
          17,54,55,70,72-77
         </a>
         ]. However, other studies have not shown a clear relationship between comorbidity burden and outcomes [
         <a href="#rid65">
          65,78,79
         </a>
         ]. Cross study comparisons can be difficult due to differences in treatment and patient selection. The implications of comorbidity may also differ by treatment type and by characterization of the comorbid conditions themselves. Because of a lack of uniform collection of comorbidity data in many multi-center trials of AML, much of the evidence supporting assessment and management of older patients with comorbid illnesses is limited to smaller studies and population-based studies.
        </p>
        <p>
         Major barriers to successful treatment in older patients include decreased bone marrow regenerative capacity (even after successful leukemia cytoreduction), an inability to tolerate long periods of pancytopenia, malnutrition, and the nephrotoxicity of certain drugs (eg, aminoglycosides, amphotericin). Evidence is limited regarding the implications of individual comorbid conditions on treatment tolerance beyond those conditions that are known contraindications for specific chemotherapeutic agents. As an example, the presence of diabetes and hyperglycemia may increase the risk of mortality for older adults with AML [
         <a href="#rid80">
          80,81
         </a>
         ], but further research is needed to determine if changes in management of comorbid conditions will influence outcomes.
        </p>
        <p class="headingAnchor" id="H1057813590">
         <span class="h2">
          Measures of comorbidity
         </span>
         <span class="headingEndMark">
          —
         </span>
         A modified Charlson comorbidity index (CCI) and the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) are frequently used to assess comorbidity in the setting of AML, even though neither test was originally designed for use in older adults with AML. Use of either the CCI or HCT-CI to assess comorbidity burden can inform decisions and management. Studies utilizing the CCI and HCT-CI in AML are represented below.
        </p>
        <p class="headingAnchor" id="H15843379">
         <span class="h3">
          Charlson comorbidity index
         </span>
         <span class="headingEndMark">
          —
         </span>
         The original Charlson comorbidity index (CCI) was devised as a measure of comorbidities in older adults. A revised version has been utilized in studies of older adults with AML with mixed results  (
         <a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">
          table 3
         </a>
         ). Small retrospective studies and large population-based studies have evaluated CCI in older adults with AML [
         <a href="#rid17">
          17,70,78,79
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of SEER/Medicare data representing 5480 people ≥65 years of age with newly diagnosed AML, 45 percent had at least one major comorbid condition reflected by CCI ≥1 [
         <a href="#rid17">
          17
         </a>
         ]. Higher scores on the claims-based CCI were independently associated with higher 30-day mortality and shorter survival, after adjusting for age and receipt of therapy. Performance status was not included in the analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Danish study representing 2792 patients diagnosed with AML between 2000 and 2012 identified 40 percent with at least one major comorbid condition (modified CCI ≥1); only 25 percent of those receiving intensive therapy (n = 1467) had CCI ≥1 [
         <a href="#rid79">
          79
         </a>
         ]. Among patients receiving intensive therapy, poor performance status but not comorbidity was associated with remission and early mortality. These results suggest that comorbidity impacted treatment decisions.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15843386">
         <span class="h3">
          HCT comorbidity index
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hematopoietic cell transplantation specific comorbidity index (HCT-CI) was designed to predict outcomes in younger adults undergoing HCT  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ). It has had mixed results in predicting outcome in older adults with AML. More details on the HCT-CI are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3538.html" rel="external">
          "Hematopoietic support after hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Moderate-sized retrospective studies have evaluated the impact of HCT-CI in older adults with AML [
         <a href="#rid55">
          55,72,73,75,76,78
         </a>
         ]. Analysis of data from the multi-center ALFA-9803 trial, in which patients ≥65 years of age (n = 416) with newly diagnosed AML were treated with intensive induction therapy, showed that an HCT-CI ≥3 was independently associated with worse OS. The prevalence of HCT ≥3 in the clinical trial was low (&lt;10 percent) [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         An augmented HCT-CI has been developed and tested in the setting of AML. This augmented index includes the comorbidities from the HCT-CI plus the addition of hypoalbuminemia, thrombocytopenia, and lactate dehydrogenase (LDH) [
         <a href="#rid47">
          47
         </a>
         ]. Compared with the original HCT-CI, the augmented index better predicted survival in combination with age and cytogenetic/molecular risk among a large cohort of adults treated for AML.
        </p>
        <p class="headingAnchor" id="H5729659">
         <span class="h2">
          Cognitive impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence and prevalence of cognitive impairment increases with age. Pretreatment cognitive impairment may increase the risk of complications during and after intensive therapy for AML. Cognitive screening may identify patients who are at higher risk for complications, including delirium. (See
         <a class="medical medical_review" href="/z/d/html/98592.html" rel="external">
          "Assessment of decision-making capacity in adults"
         </a>
         .)
        </p>
        <p>
         Research in this area is still limited. A study of 54 patients with AML/MDS documented impaired performance on a battery of cognitive tests in up to 40 percent of the study population before treatment [
         <a href="#rid82">
          82
         </a>
         ]. Similarly, a second small prospective study detected cognitive impairment in 30.5 percent of patients (mean age 70.8) prior to treatment with intensive induction chemotherapy [
         <a href="#rid52">
          52
         </a>
         ]. In further analysis of this population, patients with cognitive impairment had a shorter median survival (5.2 versus 15.6 months). Results remained significant after controlling for age, sex, ECOG performance status, cytogenetic risk, prior MDS, and hemoglobin (HR 2.5; 95% CI 1.2-5.5) [
         <a href="#rid65">
          65
         </a>
         ]. Multi-site studies are on-going to determine whether brief cognitive screening can identify older adults at risk for poor treatment tolerance. It is reasonable, however, to incorporate a brief cognitive screen into pretreatment evaluations as results can inform management (with a focus on prevention of delirium) and have implications for considerations of capacity during informed decision-making.
        </p>
        <p>
         A large single institution study evaluated adults aged ≥75 years who were seen in consultation for myeloma, leukemia or lymphoma. This study identified a high prevalence of cognitive impairment using simple screening tools for executive dysfunction (35 percent impaired using the Clock-in-the-Box test) and working memory (17 percent impaired using the five-word delayed recall) [
         <a href="#rid83">
          83
         </a>
         ]. Impaired working memory was associated with worse survival, including when patients were stratified by aggressive versus indolent malignancy. In multivariate analysis, impaired working memory (≤2 out of 5 words correct) was associated with worse survival controlled for age, comorbidity and disease aggressiveness (OR 0.26, 95% CI 0.13-0.5).
        </p>
        <p class="headingAnchor" id="H320162">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific symptoms present at the time of pretreatment assessment may be prognostic for older adults with AML. A multi-site study of pretreatment geriatric assessment for older adults with MDS or AML identified a high level of fatigue (score &gt;50 on the EORTC-QLQ C30 fatigue subscale) as independently predictive of worse OS [
         <a href="#rid54">
          54
         </a>
         ]. A single institution study of older adults with newly diagnosed AML identified pain (reported as more often versus less often) as an independent prognostic factor for increased risk of death [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H320169">
         <span class="h2">
          Comprehensive geriatric assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment assessment for older adults with AML should include factors that may differ between adults with the same chronologic age and tumor biology. A comprehensive and systematic approach should be used for evaluation since many patients present with more than one impairment or vulnerability. Geriatric assessment is recommended for adults ≥65 years of age who are considered for chemotherapy [
         <a href="#rid84">
          84
         </a>
         ]. Both single institution and multi-site studies indicate that geriatric assessment is feasible in the context of AML therapeutic decision-making [
         <a href="#rid52">
          52,54,85
         </a>
         ]. A feasibility study showed that a primarily self-reported geriatric assessment could be administered in approximately 30 minutes (approximately 10 minutes of staff time) [
         <a href="#rid86">
          86
         </a>
         ]. As discussed above, geriatric assessment can detect multiple vulnerabilities among older adults with AML that may not be captured in routine clinical practice (eg, depression, distress, impairment in basic and instrumental activities of daily living, objectively measured physical impairment cognitive impairment and comorbidity). (See
         <a class="local">
          'Performance status'
         </a>
         above.)
        </p>
        <p>
         At present, the evidence is strongest to support the addition of more refined measures of physical function to standard oncology performance scales. We recommend the assessment of ADLs and IADLs for all patients and consideration of physical performance testing (SPPB or gait speed) for patients with good performance status to identify vulnerability. We also recommend the use of a standardized measure of comorbidity burden (modified CCI, HCT-CI or augmented HCT-CI). Consideration should be given to screening for cognitive impairment. We suggest considering the five-word delayed recall as a practical screening test.
        </p>
        <p>
         At present there is no validated definition of "fitness" or "unfitness" in the context of AML therapy. Available evidence supports poor performance status, ADL impairment, and high comorbidity burden as vulnerabilities that can characterize individuals at greatest risk for treatment-related toxicity and shorter survival. Studies are underway to characterize "fitness" and "frailty" in the context of more intensive and less intensive therapies [
         <a href="#rid87">
          87,88
         </a>
         ]. In addition, pretreatment geriatric assessment can also identify vulnerabilities that can been intervened upon during therapy to improve treatment tolerance and survivorship.
        </p>
        <p class="headingAnchor" id="H15843393">
         <span class="h1">
          TREATMENT CHOICES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A discussion with the patient, with or without loved ones and caregivers, should include a review of the following [
         <a href="#rid89">
          89
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prognostic information to enable informed decisions regarding choice of treatment. Regardless of treatment choice, patients and their family members often report not being offered alternative treatment options and tend to overestimate the chance of cure [
         <a href="#rid90">
          90
         </a>
         ]. Written consent forms required for clinical trials may serve an educational role, even for those who do not desire to enter into a formal study.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Implications of the diagnosis and treatment on quality of life [
         <a href="#rid91">
          91,92
         </a>
         ], functional independence [
         <a href="#rid93">
          93-95
         </a>
         ], and social support.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Who has durable power of attorney for health issues if the patient becomes unable to make decisions?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Does the patient have an updated will? Do other members of the family know where this information is kept? Will the family have access to adequate funds while the patient is hospitalized?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A discussion concerning "code" status and the possibility that the patient might need to be transferred to an intensive care unit, with its attendant morbidity and mortality [
         <a href="#rid96">
          96
         </a>
         ]. This should include issues related to "do not resuscitate" and "do not intubate" orders, such that the patient and family can make properly informed decisions on these matters. (See
         <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">
          "Advance care planning and advance directives"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The effect on the patient's employment. Most patients will not be able to return to even part-time work until the completion of induction and consolidation chemotherapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1707757895">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116628.html" rel="external">
          "Society guideline links: Acute myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15844597">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15790.html" rel="external">
          "Patient education: Acute myeloid leukemia (AML) (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15491.html" rel="external">
          "Patient education: Leukemia in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/681.html" rel="external">
          "Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15844604">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Prognosis for older patients with acute myeloid leukemia (AML) is generally inferior to that of younger patients. There is no consensus definition of "older adult" regarding management of AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Age is only one factor to be considered when selecting treatment for older adults with AML. We favor functional assessment of the individual rather than chronologic age, per se. Treatment decisions are individualized and should consider age, functional status, comorbid conditions, and clinical and cytogenetic features of the leukemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Survival for patients with AML decreases with increasing age  (
         <a class="graphic graphic_figure graphicRef75742" href="/z/d/graphic/75742.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Both patient-specific factors and biologic features of the leukemia contribute to inferior outcomes in older patients. Important risk factors include (see
         <a class="local">
          'Risk factors'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired performance status
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cytogenetic and genetic abnormalities – Adverse features (eg, abnormalities of chromosomes 5 or 7 or complex karyotypes) and mutations (eg, mutated
         <em>
          TP53
         </em>
         ) are more common in older patients
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         White blood cell count at diagnosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Secondary leukemia (ie, AML arising from an antecedent myelodysplastic or myeloproliferative neoplasm)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Therapy-related myeloid neoplasms
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         . (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General evaluation
         </strong>
         – All patients with AML, regardless of age, require a general pretreatment evaluation, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4525.html" rel="external">
          "Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Pretreatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physical functioning
         </strong>
         – Assessment of older individuals should include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Performance status
         </strong>
         – Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status  (
         <a class="graphic graphic_table graphicRef72901 graphicRef58785" href="/z/d/graphic/72901.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="local">
          'Performance status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Activities of daily living (ADLs)
         </strong>
         – Basic ADLs (eg, feeding, grooming, transferring, toileting) and instrumental ADLs (IADLs; activities required to live independently in the community, such as shopping, managing finances, housekeeping, preparing meals, taking medications). (See
         <a class="local">
          'Activities of daily living'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Physical performance tests
         </strong>
         – The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nia.nih.gov%2Fresearch%2Flabs%2Fleps%2Fshort-physical-performance-battery-sppb&amp;token=Ngvz3u3Ql93gI9weXBPg6VtOf8n2HWudIoo%2FrOWiIs374avkeEunE01ednwN5QQaicfILokZzILD9X%2BBLpEalBGjmFaV%2FDZCQ%2BRn9ks0NDU%3D&amp;TOPIC_ID=86177" target="_blank">
          Short Physical Performance Battery
         </a>
         (SPPB), a measure of lower extremity functioning. (See
         <a class="local">
          'Physical performance tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Comorbidities
         </strong>
         – Patients with chronic cardiac, pulmonary, hepatic, or renal disorders or diabetes experience greater acute toxicity from chemotherapy. (See
         <a class="local">
          'Comorbid conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Either of the following measures of comorbidities  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ) should be applied to assess severity of comorbidities:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Charlson comorbidity index (CCI). (See
         <a class="local">
          'Charlson comorbidity index'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematopoietic cell transplantation specific comorbidity index (HCT-CI). (See
         <a class="local">
          'HCT comorbidity index'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cognitive screening
         </strong>
         – Cognitive screening is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/98592.html" rel="external">
          "Assessment of decision-making capacity in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Geriatric assessment
         </strong>
         – For selected patients, a comprehensive geriatric evaluation may be useful to assess impairment and/or vulnerability. (See
         <a class="local">
          'Comprehensive geriatric assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment choices
         </strong>
         – Discussions with the patient, with or without loved ones and caregivers, should include frank conversation to enable informed decision-making. (See
         <a class="local">
          'Treatment choices'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Important topics include the individual's overall prognosis and the impact of treatments on quality of life, functional independence, and social support. Choices regarding the patient's willingness to be resuscitated, intubated, and/or transferred to an intensive care unit should be addressed.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrara F, Annunziata M, Copia C, et al. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leoni F, Ciolli S, Nozzoli C, et al. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica 1997; 82:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juliusson G, Höglund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age &gt; or = 75 years. Cancer 2004; 101:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31:3110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30:3924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uy GL, Mandrekar SJ, Laumann K, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 2017; 1:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           British Committee for Standards in Haematology, Milligan DW, Grimwade D, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012; 97:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros BC, Satram-Hoang S, Hurst D, et al. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 2015; 94:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29:4417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Cuadrón D, Serrano J, Gil C, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia 2021; 35:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juliusson G, Lazarevic V, Hörstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 2012; 119:3890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamedali H, Breunis H, Timilshina N, et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 2012; 36:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valcárcel D, Montesinos P, Sánchez-Ortega I, et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer 2012; 118:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 2015; 125:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998; 21:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001; 98:3500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Holt B, Breems DA, Berna Beverloo H, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007; 136:96.
          </a>
         </li>
         <li class="breakAll">
          LeBeau MM, Larson RA. Cytogenetics and neoplasia. In: Hematology Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moorman AV, Roman E, Cartwright RA, Morgan GJ. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia. Br J Cancer 2002; 86:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:5580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostronoff F, Othus M, Lazenby M, et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol 2015; 33:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118:6920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:3622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwind S, Marcucci G, Kohlschmidt J, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011; 118:4188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickson GJ, Bustraan S, Hills RK, et al. The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia. Br J Haematol 2016; 172:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorror ML, Storer BE, Fathi AT, et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol 2017; 3:1675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorror ML, Storer BE, Nyland J, Estey EH. Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. JAMA Oncol 2019; 5:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116:4422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Röllig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011; 59:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedding U, Röhrig B, Klippstein A, et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006; 132:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013; 98:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman AE, Motyckova G, Fega KR, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013; 37:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandinelli S, Lauretani F, Boscherini V, et al. A randomized, controlled trial of disability prevention in frail older patients screened in primary care: the FRASI study. Design and baseline evaluation. Aging Clin Exp Res 2006; 18:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corsonello A, Lattanzio F, Pedone C, et al. Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals. Rejuvenation Res 2012; 15:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freire AN, Guerra RO, Alvarado B, et al. Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil. J Aging Health 2012; 24:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49:M85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guralnik JM, Ferrucci L, Simonsick EM, et al. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995; 332:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 2000; 55:M221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostir GV, Volpato S, Fried LP, et al. Reliability and sensitivity to change assessed for a summary measure of lower body function: results from the Women's Health and Aging Study. J Clin Epidemiol 2002; 55:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Studenski S, Perera S, Wallace D, et al. Physical performance measures in the clinical setting. J Am Geriatr Soc 2003; 51:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volpato S, Cavalieri M, Sioulis F, et al. Predictive value of the Short Physical Performance Battery following hospitalization in older patients. J Gerontol A Biol Sci Med Sci 2011; 66:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013; 121:4287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timilshina N, Breunis H, Tomlinson G, et al. Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients? Leuk Res 2016; 47:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011; 305:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perera S, Patel KV, Rosano C, et al. Gait Speed Predicts Incident Disability: A Pooled Analysis. J Gerontol A Biol Sci Med Sci 2016; 71:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood 2019; 134:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalin B, Pijnappel EN, van Gelder M, et al. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. Cancer Epidemiol 2018; 57:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djunic I, Virijevic M, Novkovic A, et al. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. Hematology 2012; 17:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breccia M, Frustaci AM, Cannella L, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol 2009; 27:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savic A, Kvrgic V, Rajic N, et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res 2012; 36:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 93:1806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wass M, Hitz F, Schaffrath J, et al. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS One 2016; 11:e0164587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harb AJ, Tan W, Wilding GE, et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 115:2472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østgård LS, Nørgaard JM, Sengeløv H, et al. Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia 2015; 29:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawfik B, Pardee TS, Isom S, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol 2016; 7:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhlman P, Isom S, Pardee TS, et al. Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. Support Care Cancer 2019; 27:2877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hshieh TT, Jung WF, Grande LJ, et al. Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol 2018; 4:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 2018; 36:2326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klepin HD, Ritchie EK, Sanford BL, et al. Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance). J Clin Oncol (ASCO Annual Meeting Abstracts) 2014; 32:Abstract 7102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klepin HD, Ritchie E, Major-Elechi B, et al. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol 2020; 11:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter RB, Michaelis LC, Othus M, et al. Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 2018; 93:E49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grishina O, Schmoor C, Döhner K, et al. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients &gt;60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer 2015; 15:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Jawahri A, Nelson-Lowe M, VanDusen H, et al. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist 2019; 24:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Jawahri A, Abel GA, Traeger L, et al. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia 2019; 33:2393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinsley SM, Sutton SK, Thapa R, et al. Treatment Choices: A Quality of Life Comparison in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 2017; 17S:S75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klepin HD, Tooze JA, Pardee TS, et al. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. J Am Geriatr Soc 2016; 64:1988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alibhai SM, Breunis H, Timilshina N, et al. Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol 2015; 6:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timilshina N, Breunis H, Tomlinson GA, et al. Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy. Leukemia 2019; 33:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbat A, Chaoui D, Montani D, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol 2005; 129:350.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86177 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16455952" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Age and acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19008455" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19776405" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : High-dose daunorubicin in older patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508168" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488990" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Acute myeloid leukemia and myelodysplastic syndromes in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9549923" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9402748" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Idarubicin in induction treatment of acute myeloid leukemia in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14632771" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15241830" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The benefit of induction chemotherapy in patients age&gt;or = 75 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341661" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23897964" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22851554" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22482940" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29034366" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16435386" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17054678" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Guidelines on the management of acute myeloid leukaemia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22773600" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Survival for older patients with acute myeloid leukemia: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25791241" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12469764" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The difficult problem of acute myeloid leukemia in the older adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969499" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12123403" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The outcomes and costs of acute myeloid leukemia among the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33077867" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22383796" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acute myeloid leukemia in the real world: why population-based registries are needed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22727251" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722406" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19344426" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9129038" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19047294" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21717435" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25550361" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648393" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9537199" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11732508" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dependence of age-specific incidence of acute myeloid leukemia on karyotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17129222" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17129222" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2910364" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520776" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953849" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858393" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20026798" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25713434" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22291079" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22031865" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20656931" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828125" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26847745" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28880971" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31095246" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131036" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20668231" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20442365" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22091497" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16821071" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Impairment in functional status and survival in patients with acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22875615" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23747082" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167299" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A randomized, controlled trial of disability prevention in frail older patients screened in primary care: the FRASI study. Design and baseline evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22004280" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prognostic significance of the short physical performance battery in older patients discharged from acute care hospitals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22422762" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8126356" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7838189" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10811152" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393080" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reliability and sensitivity to change assessed for a summary measure of lower body function: results from the Women's Health and Aging Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588574" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Physical performance measures in the clinical setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20861145" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Predictive value of the Short Physical Performance Battery following hospitalization in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23550038" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27337292" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Do quality of life, physical function, or the Wheatley index at diagnosis predict 1-year mortality with intensive chemotherapy in older acute myeloid leukemia patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205966" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Gait speed and survival in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297942" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Gait Speed Predicts Incident Disability: A Pooled Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31167800" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17326052" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30347337" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17223919" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22664041" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19274612" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22192632" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18838471" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27732646" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19322894" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25092141" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26527394" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30554278" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973668" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29494732" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29782209" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31668825" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29164656" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26008690" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients&gt;60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14762444" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30139841" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30923318" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28760305" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Treatment Choices: A Quality of Life Comparison in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27627675" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25944029" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29884902" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15842658" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Prognosis of patients with acute myeloid leukaemia admitted to intensive care.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
